Jan 23, 2017
Seth Yakatan, CEO of Kalytera, a company developing synthetic CBD compounds focused on different diseases including Osteoporosis, Prader-Willi Syndrome, and Obesity says follow the letter of the law, expand to related businesses and if possible, do as his company has done:
“Turn to synthetic cannabinoids or small molecule derivatives, which could allow for similar results for medical patients and less overall risk for business owners given the federal illegality of cannabis.”
Dec 27, 2016
If there’s any industry in the US that’s growing at a rate like that of the tech sector in the late ‘90s, it’s the cannabis space. 28 states now allow for the medical consumption of cannabis, eight of which allow for its use as a recreational substance, and there’s no sign that state-specific industries will slow down their rate of growth. https://www.equities.com/news/innovation-in-the-cannabis-industry
Dec 26, 2016
This year saw big election wins for marijuana in several states. In addition, Colorado crossed the $1 billion mark for annual marijuana sales. Now a new year is almost here and a new presidential administration for the cannabis industry to navigate. It's time to look ahead and see what's in store for the cannabis industry in 2017. http://www.forbes.com/sites/debraborchardt/2016/12/26/here-are-the-top-2017-predictions-for-the-marijuana-industry/#26e7e71f689a
Dec 20, 2016
It’s a prognosis patients never want to hear: “No successful treatment regimens have been devised.” That’s the American Migraine Foundation’s summary of an ailment known as New Daily Persistent Headache (NDPH). Since Jonathan Zaid was diagnosed with the rare condition in 2007 at age 14, he’s been prescribed more than 40 different drugs in a futile attempt to alleviate migraines so debilitating that he couldn’t concentrate or fall asleep at night. Then, in 2014, his physician shifted tactics and prescribed a surprising new medication that almost immediately improved Zaid’s quality of life http://www.ozy.com/fast-forward/the-new-wonder-drug-synthetic-cannabis/74514
Dec 10, 2016
Despite its continuing hardline stance against marijuana, the US Drug Enforcement Agency (DEA) has shown some signs of relenting and this summer opened the door to allowing more farms to grow cannabis for official research purposes. That’s an important step forward that may change the potential marijuana has for medical treatment. Up to this point, researchers have had to depend on just one farm at the University of Mississippi to supply cannabis for all studies. https://www.theguardian.com/lifeandstyle/2016/dec/10/medical-marijuana-research-new-treatments
Nov 01, 2016
On November 8, constituents in nine states will vote on medical or recreational, known as adult use, marijuana laws in what could be the largest policy decision pot has faced since being outlawed by the U.S. government in 1937. In California particularly, legalizing recreational weed for adults (defined in California’s Prop. 64, the Adult Use of Marijuana Act, for people 21 years and older) will have ramifications beyond the state’s borders. That’s because California’s projected dual market of medical and recreational pot is larger than those of Colorado, Oregon, Washington and Alaska combined—the first four states to have legalized weed. http://www.playboy.com/articles/can-medical-and-recreational-weed-co-exist
Oct 17, 2016
Indeed, for the right type of funder, doling out money to marijuana-related businesses is a promising market—certainly in the short term because these companies are so capital-starved. Because marijuana is still classified by the feds as an illegal drug, many related businesses can’t even get a bank account much less access to bank loans or more traditional funding. Many alternative funders are also unwilling to lend to marijuana-related businesses, which has left a significant void that’s beginning to be filled by opportunistic private equity investors, venture capitalists and others. http://debanked.com/2016/10/some-alternative-funders-see-pot-as-next-big-market-opportunity/
Oct 07, 2016
Given its diverse pool of user effects ranging from “the munchies” to pain relief and seizure reduction, it’s safe to say cannabis does many things. But one of the somewhat lesser-known benefits of cannabis is its effect on bone health. http://extract.suntimes.com/news/10/153/22465/marijuana-bone-health-cannabis-next-big-thing-osteoporosis-treatment
Sep 07, 2016
In a new trend for the federally prohibited plant, drug research and development companies like Insys Therapeutics, GW Pharmaceuticals, and Kalytera Therapeutics are researching and developing cannabis into pharmaceutical drugs. But it’s the U.S. headquartered firms who historically lead the way in producing innovative molecules that become drugs, according to the MIT principles and practice of drug development. https://www.marijuanatimes.org/the-future-of-clinical-cannabis-part-1/
Aug 29, 2016
Earlier this month the Drug Enforcement Administration (DEA) announced it would open some doors for research into cannabis. http://www.nnbw.com/news/dea-marijuana-remains-a-schedule-i-controlled-substance/
Aug 28, 2016
When it comes to technological developments in the widely varied cannabis industry, some come about due to the natural instinct to innovate, and some come about as a necessity to adapt with the ever-changing landscape that is the medical and recreational cannabis space. Over the years, businesses, researchers, advocates, and everyone in between has had their crack at assisting in ushering in new technologies and practices. http://theleafonline.com/c/business/2016/08/cannabis-technology-helps-patients-society/
Aug 26, 2016
Presidential candidate Hillary Clinton announced that she will reschedule cannabis if elected President, as public outrage continues to grow since the federal DEA once again swept science aside in order to declare that marijuana as a “dangerous drug” with “no medical value, no accepted medical use AND a high potential for abuse.” In the real world, cannabis has been shown to be a safe and effective medication supported by a majority of Americans and that its use by minors, for example, is lower when cannabis is legal than when it is banned, meaning that legalization actually reduces drug abuse especially use by minors. http://theleafonline.com/c/business/2016/08/clinton-others-reject-dea-ban-medical-cannabis/
Aug 13, 2016
It’s a federal decision that could mean a sea change for the cannabis world. The Drug Enforcement Agency (DEA) released a new policy on Thursday morning that will, for the first time, supply quality cannabis to the world of American researchers. The new policy statement from the DEA (in consultation with NIDA and the FDA) outlines a new approach to the availability of medical grade marijuana for science. https://www.marijuanatimes.org/dea-paves-narrow-path-for-cannabis-research/
Aug 12, 2016
Supporters of cannabis legalization got a rare bit of good news from the Drug Enforcement Administration Thursday, as the government announced in the Federal Register that the DEA will expand the number of places allowed to grow marijuana for research purposes. The policy change will be used to study the value of cannabis for treating chronic pain and epilepsy, among other purposes. https://www.equities.com/news/cannabis-industry-leaders-respond-to-deas-refusal-to-remove-marijuana-as-schedule-i-drug
Aug 11, 2016
This November, California voters are expected to pass Proposition 64, the Adult Use of Marijuana Act, which will effectively make recreational pot use legal in the state. The policy shift could spawn a large and emergent market for marijuana tourism — a prospect that looks attractive to many, particularly given the state’s ongoing budgetary crises. While visions of sativa wine tasting and THC surf lessons may float through entrepreneurs' heads, some cannabis businesses in the Los Angeles area say they will be largely unaffected by the legalization of recreational marijuana. According to these business owners, economic growth and meaningful development will be largely inhibited so long as the federal Drug Enforcement Administration continues to categorize cannabis as Schedule http://www.laweekly.com/news/why-recreational-marijuana-may-not-benefit-cannabis-businesses-until-dea-rescheduling-7239494
Aug 11, 2016
It’s no longer a secret that the cannabis industry is growing in a big way. In a remarkably short amount of time, cannabis has already been fully legalized in five states and legitimized in 20 other states and the District of Columbia for medicinal purposes, with legalization likely in many other states in the coming months and years. Today, cannabis is an industry with the potential for multiple billions of dollars in growth. https://www.equities.com/news/cannabis-business-leaders-advice-for-entrepreneurs-and-investors
Aug 11, 2016
The government’s decision Thursday to allow more growers to produce marijuana for medical experimentation could pave the way for the end of the drug’s prohibition — eventually. http://www.marketwatch.com/story/dea-sends-medical-marijuana-back-for-more-research-2016-08-11
Mar 31, 2016
Our co-founder and CEO Saul Kaye discusses some of the medical conditions we believe medical cannabis treats. We would love to hear from you: What medical conditions do you think medical cannabis can treat? https://www.facebook.com/CannaTech2015/videos/1578369659142955/
Mar 09, 2016
On February 9, the FDA sent out a number of warning letters to companies that make and sell products containing cannabidiol (CBD), a type of cannabinoid found in marijuana. Some of the products that the FDA tested contained no CBD in them at all. all. https://www.forbes.com/sites/debraborchardt/2016/03/09/fda-sends-warning-letters-to-cannabis-companies/#1139a42f5d06
Apr 21, 2016
Investors who are choosing among the hundreds of businesses involved in the emerging, yet growing cannabis industry are often caught in a conundrum as to whether medical companies are a safer investment compared to recreational businesses.
Apr 20, 2016
If approved by the Food and Drug Administration, GW Pharmaceuticals PLC’s cannabis-derived drug, which treats child epilepsy, would be the first of its kind in the U.S. and while FDA approval is by no means a sure thing, U.K.-based GW UK:GWP announced positive phase-three trial results for the drug, Epidiolex, on March 14. http://www.marketwatch.com/story/five-things-to-know-about-what-could-be-americas-first-cannabis-derived-drug-2016-03-15
Apr 16, 2016
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has signed a preclinical research agreement with Ramot at Tel Aviv University (“Ramot”) to evaluate three Kalytera drug candidates to assess their potential ability to strengthen bone in persons with osteogenesis imperfecta (“OI”), a rare group of genetic disorders characterized by bones that are brittle and break easily. https://kalytera.co/osteogenesis-imperfecta-preclinical-study/
Apr 12, 2016
As public support for marijuana legalization continues to rise and after 23 states plus the District of Columbia legalized it for medical use, questions about how traditional health care plays a role in the industry are becoming more pressing. http://www.rgj.com/story/news/politics/2016/02/02/one-nation-medical-marijuana-faces-uncertain-future-us-health-care-system/78655514/
Apr 12, 2016
The U.S. Drug Enforcement Agency made a rare move in December, and it’s good news for those who hold FDA-approved cannabidiol (CBD) clinical trials and have learned their regulatory requirements will be eased. http://www.myvoicenation.com/promotions/viewEmailByDistLstDelivId/vmg-74774
